Company Overview and News
Market players will be looking for signs of a sustained recovery in the local stock market after a turbulent week in global markets, even as the 11th Malaysia Plan (11MP) and China’s third-quarter gross domestic product data — due to be released this Friday — will be in focus.
SLLXF 0048 4219 5109 0032
YTL Hospitality REIT (Sept 5, RM1.20) Maintain buy with a higher fair value (FV) of RM1.35: We raise our financial year 2019-2020 forward (FY19-20F) forecasts by 2.4% and 2.2% to RM149.2 million and RM155.5 million respectively. We also introduce our FY21F earnings forecast at RM160.1 million. We maintain our “buy” call on YTL Hospitality Real Estate Investment Trust (YTL REIT) with a revised FV of RM1.
YTL Hospitality REIT (Aug 15, RM1.21) Maintain buy with an unchanged dividend discount model-derived target price (TP) of RM1.32. The report was issued after YTL REIT entered into a conditional sale and purchase agreement with Niseko Village K K, an indirect wholly-owned subsidiary of YTL Corp Bhd for the acquisition of the Green Leaf Niseko Village for a cash consideration of ¥6 billion (RM222.5 million).
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF
PETALING JAYA: YTL Hospitality Real Estate Investment Trust (REIT) recorded a 10.95% jump in earnings to RM67.55mil for the fourth quarter to June 30 on the back of the better performance of its Australian properties as a result of an increase in room sales following the completion of a refurbishment exercise.
SLLXF 5109 BSMAF 1818
KUALA LUMPUR (July 31): Based on corporate announcements and news flow today, companies in focus on Wednesday (Aug 1) may include: Scomi Group Bhd, YTL Hospitality Real Estate Investment Trust (REIT), Serba Dinamik Holdings Bhd, Perusahaan Sadur Timah Malaysia Bhd, Globetronics Technology Bhd, Opcom Holdings Bhd, Halex Holdings Bhd and Datasonic Group Bhd.
SLLXF 5436 5216 4863 0035 5109 7158 HIL MYTEF 5151 7022 GBTKF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...